| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CTR |
| Uniprot No | P30988 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-474aa |
| 氨基酸序列 | MRFTFTSRCLALFLLLNHPTPILPAFSNQTYPTIEPKPFLYVVGRKKMMDAQYKCYDRMQQLPAYQGEGPYCNRTWDGWLCWDDTPAGVLSYQFCPDYFPDFDPSEKVTKYCDEKGVWFKHPENNRTWSNYTMCNAFTPEKLKNAYVLYYLAIVGHSLSIFTLVISLGIFVFFRSLGCQRVTLHKNMFLTYILNSMIIIIHLVEVVPNGELVRRDPVSCKILHFFHQYMMACNYFWMLCEGIYLHTLIVVAVFTEKQRLRWYYLLGWGFPLVPTTIHAITRAVYFNDNCWLSVETHLLYIIHGPVMAALVVNFFFLLNIVRVLVTKMRETHEAESHMYLKAVKATMILVPLLGIQFVVFPWRPSNKMLGKIYDYVMHSLIHFQGFFVATIYCFCNNEVQTTVKRQWAQFKIQWNQRWGRRPSNRSARAAAAAAEAGDIPIYICHQELRNEPANNQGEESAEIIPLNIIEQESSA |
| 预测分子量 | 55,3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CTR(降钙素受体)重组蛋白的3篇代表性文献概览，涵盖表达、结构、功能及应用研究：
---
1. **文献名称**：*Expression and Functional Characterization of Recombinant Human Calcitonin Receptor in Mammalian Cells*
**作者**：Lin, H.Y., et al.
**摘要**：本研究成功在哺乳动物细胞(HEK293)中表达了重组人降钙素受体(CTR)，并通过配体结合实验和cAMP信号通路分析验证了其功能活性。结果显示，重组CTR对降钙素具有高亲和力，并能够有效激活下游信号通路，为后续受体功能研究提供模型。
2. **文献名称**：*Structural Insights into the Activation Mechanism of the Calcitonin Receptor via Cryo-EM*
**作者**：Pal, K., et al.
**摘要**：通过冷冻电镜技术解析了重组CTR与降钙素类似物结合的三维结构，揭示了受体跨膜结构域的构象变化及G蛋白偶联机制。该研究为靶向CTR的药物设计提供了关键结构生物学依据。
3. **文献名称**：*Site-Directed Mutagenesis of the Calcitonin Receptor: Impact on Ligand Binding and Signaling*
**作者**：Seck, T., et al.
**摘要**：利用重组CTR蛋白进行定点突变，发现其胞外域特定氨基酸残基对降钙素结合至关重要，同时跨膜区的突变显著影响受体的信号转导效率。研究阐明了CTR与配体相互作用的分子基础。
---
**备注**：上述文献为示例性质，实际引用需根据具体研究方向补充真实文献信息。若需扩展，可进一步检索近年关于CTR重组蛋白在疾病模型(如骨质疏松、癌症)中的应用研究。
CTR (Calcitonin Receptor) recombinant protein is a biologically engineered molecule central to studying calcium homeostasis and related physiological processes. The calcitonin receptor, a G protein-coupled receptor (GPCR), primarily binds calcitonin, a hormone involved in regulating blood calcium levels by inhibiting osteoclast activity and promoting renal calcium excretion. Recombinant CTR proteins are generated through heterologous expression systems, such as mammalian cells (e.g., HEK293) or insect cells (e.g., Sf9), using molecular cloning techniques to insert the CTR gene into expression vectors. This allows large-scale production of purified, functional receptors for research and therapeutic applications.
The development of CTR recombinant proteins has advanced structural biology studies, enabling cryo-electron microscopy and X-ray crystallography to resolve its activation mechanisms and ligand-binding domains. These insights are critical for designing drugs targeting bone disorders (e.g., osteoporosis), hypercalcemia, and cancers where CTR signaling is dysregulated. Additionally, recombinant CTR serves as a tool for screening calcitonin analogs or small-molecule modulators, optimizing pharmacokinetics, and evaluating receptor-ligand interactions in vitro. Challenges remain in maintaining receptor stability and post-translational modifications during production, which affect ligand affinity and signaling fidelity. Ongoing research focuses on improving expression systems and purification protocols to enhance CTR functionality, paving the way for novel therapies and deeper understanding of GPCR-mediated pathways in metabolic diseases.
×
